These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20080830)

  • 1. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Aapro M; Fabi A; Nolè F; Medici M; Steger G; Bachmann C; Roncoroni S; Roila F
    Ann Oncol; 2010 May; 21(5):1083-8. PubMed ID: 20080830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
    Shi Q; Li W; Li H; Le Q; Liu S; Zong S; Zheng L; Hou F
    Oncotarget; 2016 Apr; 7(17):24402-14. PubMed ID: 27015550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy.
    Choi BS; Borsaru GP; Ballinari G; Voisin D; Di Renzo N
    Leuk Lymphoma; 2014 Mar; 55(3):544-50. PubMed ID: 23772665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy.
    Sakamoto T; Kado M; Saito Y; Uchiyama K; Kanno R; Taniguchi O; Takekuma Y; Sakakibara-Konishi J; Shimizu Y; Kinoshita I; Sugawara M
    Biol Pharm Bull; 2024; 47(6):1189-1195. PubMed ID: 38897969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence.
    Celio L; Bonizzoni E; Zattarin E; Codega P; de Braud F; Aapro M
    BMC Cancer; 2019 Dec; 19(1):1268. PubMed ID: 31888544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.
    Phillips RS; Friend AJ; Gibson F; Houghton E; Gopaul S; Craig JV; Pizer B
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD007786. PubMed ID: 26836199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
    Bubalo JS; Radke JL; Bensch KG; Chen AI; Misra S; Maziarz RT
    J Oncol Pharm Pract; 2024 Mar; 30(2):304-312. PubMed ID: 37151021
    [No Abstract]   [Full Text] [Related]  

  • 8. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.
    Yamaguchi A; Saito Y; Takekuma Y; Sugawara M
    Support Care Cancer; 2023 Dec; 32(1):58. PubMed ID: 38145979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.
    Celio L; Bartsch R; Aapro M
    J Geriatr Oncol; 2023 Jul; 14(6):101537. PubMed ID: 37290207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study).
    Radhakrishnan V; Venkatakrishnan K; Perumal Kalaiyarasi J; Selvarajan G; Mahaboobasha N; Victor PV; Anbazhagan M; Sivanandam DM; Rajaraman S
    JCO Glob Oncol; 2024 Jan; 10():e2300301. PubMed ID: 38237092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data.
    Giuliani J; Bonetti A
    Curr Opin Oncol; 2020 Jul; 32(4):269-273. PubMed ID: 32541312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy.
    Shen J; Zhao J; Jin G; Li H; Jiang Y; Wu Y; Gao J; Chen F; Li J; Wang W; Li Q
    J Cancer Res Clin Oncol; 2024 May; 150(5):283. PubMed ID: 38806870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
    Basch E; Prestrud AA; Hesketh PJ; Kris MG; Feyer PC; Somerfield MR; Chesney M; Clark-Snow RA; Flaherty AM; Freundlich B; Morrow G; Rao KV; Schwartz RN; Lyman GH;
    J Clin Oncol; 2011 Nov; 29(31):4189-98. PubMed ID: 21947834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).
    Barton DL; Thanarajasingam G; Sloan JA; Diekmann B; Fuloria J; Kottschade LA; Lyss AP; Jaslowski AJ; Mazurczak MA; Blair SC; Terstriep S; Loprinzi CL
    Cancer; 2014 Nov; 120(22):3575-83. PubMed ID: 25043153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of anticipatory nausea and vomiting in breast cancer patients undergoing highly emetogenic chemotherapy.
    Alves RB; Rebouças CV; Yamada AMTD; Cruz FJSM
    Rev Assoc Med Bras (1992); 2024; 70(4):e20230937. PubMed ID: 38716933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiemetic guidelines: Have we incorporated the changes concerning carboplatin and anthracyclines?
    Redondo Capafons S; Soriano Gutierrez L; Dalmau Portulas E; Barragán Muñoz À; Martínez Robles S; Gómez-Valent M
    Farm Hosp; 2023; 47(5):183-189. PubMed ID: 37268481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?
    Capafons SR; Gutierrez LS; Portulas ED; Muñoz ÀB; Robles SM; Gómez-Valent M
    Farm Hosp; 2023; 47(5):T183-T189. PubMed ID: 37500396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
    Hui D; Puac V; Shelal Z; Liu D; Maddi R; Kaseb A; Javle M; Overman M; Yennurajalingam S; Gallagher C; Bruera E
    J Pain Symptom Manage; 2021 Aug; 62(2):223-232.e1. PubMed ID: 33388382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.
    Ryan JL; Heckler CE; Roscoe JA; Dakhil SR; Kirshner J; Flynn PJ; Hickok JT; Morrow GR
    Support Care Cancer; 2012 Jul; 20(7):1479-89. PubMed ID: 21818642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.
    Rangwala F; Zafar SY; Abernethy AP
    Curr Opin Support Palliat Care; 2012 Mar; 6(1):69-76. PubMed ID: 22228030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.